The hippocampus and TNF: Common links between chronic pain and depression

Neuroscience and Biobehavioral Reviews

Volumn 53, Issue , 2015, Pages 139-159

  Fasick, Victoria ^a   Spengler, Robert N ^b   Samankan, Shabnam ^a   Nader, Nader D ^a   Ignatowski, Tracey A ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b NanoAxis LLC   (United States)

Author keywords

Brain; Chronic pain; Comorbid; Depression; Hippocampus; Tumor necrosis factor

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; AMPA RECEPTOR; ANTICONVULSIVE AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CLONIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ETANERCEPT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; KETAMINE; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENYTOIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; TETRACYCLIC ANTIDEPRESSANT AGENT; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANALGESIC ACTIVITY; ANTIDEPRESSANT ACTIVITY; CHRONIC CONSTRICTION INJURY; CHRONIC PAIN; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCUS CERULEUS; LONG TERM DEPRESSION; MAJOR DEPRESSION; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHIC PAIN; NONHUMAN; PATHOGENESIS; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROSTRAL VENTROMEDIAL MEDULLA; STRESS; STRESS INDUCED ANALGESIA; VAGUS NERVE STIMULATION; ANIMAL; COMPLICATION; DISEASE MODEL; ENCEPHALITIS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; NERVE CELL; NOCICEPTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CHRONIC PAIN; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HIPPOCAMPUS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEURONS; PAIN PERCEPTION; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928168794     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.03.014     Document Type: Review

References (301)

1. Ackenheil M. Genetics and pathophysiology of affective disorders: relationship to fibromyalgia. Z. Rheumatol. 1998, 57(Suppl. 2):5-7.
2. Akinfiresoye L., Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology 2013, 230:291-298.
3. Al Amin H.A., Atweh S.F., Jabbur S.J., Saade N.E. Effects of ventral hippocampal lesion on thermal and mechanical nociception in neonates and adult rats. Eur. J. Neurosci. 2004, 20:3027-3034.
4. Aloe L., Properzi F., Probert L., Akassoglou K., Kassiotis G., Micera A., Fiore M. Learning abilities, NGF and BDNF brain levels in two lines of TNF-alpha transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res. 1999, 840:125-137.
5. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders: DSM-5 2013, American Psychiatric Association, Arlington, VA. 5th edition.
6. Andrews J.S., Pinder R.M. Antidepressants of the future - a critical assessment of the chemistry and pharmacology of novel antidepressants in development. Antidepressants - Milestones in Drug Therapy 2000, 115-157. Birkhäuser, Basel-Boston-Berlin. M.J. Parnham, J. Bruinvels, B.E. Leonard (Eds.).
7. Apkarian A.V., Bushnell M.C., Treede R.D., Zubieta J.K. Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain 2005, 9:463-484.
8. Arai K.Y., Roby K.F., Terranova P.F. Tumor necrosis factor alpha (TNF) suppresses cAMP response element (CRE) activity and nuclear CRE binding protein in MA-10 mouse Leydig tumor cells. Endocrine 2005, 27:17-24.
9. Aricioglu F., Regunathan S., Piletz J.E. Is agmatine an endogenous factor against stress?. Ann. N.Y. Acad. Sci. 2003, 1009:127-132.
10. Arora V., Chopra K. Possible involvement of oxido-nitrosative stress induced neuro-inflammatory cascade and monoaminergic pathway: underpinning the correlation between nociceptive and depressive behaviour in a rodent model. J. Affect. Disord. 2013, 151:1041-1052.
11. Arora V., Kuhad A., Tiwari V., Chopra K. Curcumin ameliorates reserpine-induced pain-depression dyad: behavioural, biochemical, neurochemical and molecular evidences. Psychoneuroendocrinology 2011, 36:1570-1581.
12. Asmundson G.J., Katz J. Understanding the co-occurrence of anxiety disorders and chronic pain: state-of-the-art. Depress. Anxiety 2009, 26:888-901.
13. Auguet M., Viossat I., Marin J.G., Chabrier P.E. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn. J. Pharmacol. 1995, 69:285-287.
14. Avissar S., Matuzany-Ruban A., Tzukert K., Schreiber G. Beta-arrestin-1 levels: reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am. J. Psychiatry 2004, 161:2066-2072.
15. Backonja M.M., Coe C.L., Muller D.A., Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J. Neuroimmunol. 2008, 195:157-163.
16. Bair M.J., Robinson R.L., Katon W., Kroenke K. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 2003, 163:2433-2445.
17. Baliki M.N., Geha P.Y., Apkarian A.V., Chialvo D.R. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics. J. Neurosci. 2008, 28:1398-1403.
18. Balkowiec-Iskra E., Vermehren-Schmaedick A., Balkowiec A. Tumor necrosis factor-alpha increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience 2011, 180:322-333.
19. Bansal V., Ryu S.Y., Lopez N., Allexan S., Krzyzaniak M., Eliceiri B., Baird A., Coimbra R. Vagal stimulation modulates inflammation through a ghrelin mediated mechanism in traumatic brain injury. Inflammation 2012, 35:214-220.
20. Bessis A., Bechade C., Bernard D., Roumier A. Microglial control of neuronal death and synaptic properties. Glia 2007, 55:233-238.
21. Blackburn-Munro G., Blackburn-Munro R.E. Chronic pain, chronic stress and depression: coincidence or consequence?. J. Neuroendocrinol. 2001, 13:1009-1023.
22. Blier P., Abbott F.V. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci. 2001, 26:37-43.
23. Bravo L., Mico J.A., Rey-Brea R., Perez-Nievas B., Leza J.C., Berrocoso E. Depressive-like states heighten the aversion to painful stimuli in a rat model of comorbid chronic pain and depression. Anesthesiology 2012, 117:613-625.
24. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000, 157:115-118.
25. Brustolim D., Ribeiro-dos-Santos R., Kast R.E., Altschuler E.L., Soares M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 2006, 6:903-907.
26. Butler R.K., Finn D.P. Stress-induced analgesia. Prog. Neurobiol. 2009, 88:184-202.
27. Buttini M., Mir A., Appel K., Wiederhold K.H., Limonta S., Gebicke-Haerter P.J., Boddeke H.W. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. Br. J. Pharmacol. 1997, 122:1483-1489.
28. Chabre O., Conklin B.R., Brandon S., Bourne H.R., Limbird L.E. Coupling of the alpha 2A-adrenergic receptor to multiple G-proteins. A simple approach for estimating receptor-G-protein coupling efficiency in a transient expression system. J. Biol. Chem. 1994, 269:5730-5734.
29. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiatry 2001, 50:260-265.
30. Chen J., Rasenick M.M. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J. Neurochem. 1995, 64:724-732.
31. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol. Ther. 2010, 128:519-548.
32. Cliffer K.D., Burstein R., Giesler G.J. Distributions of spinothalamic, spinohypothalamic, and spinotelencephalic fibers revealed by anterograde transport of PHA-L in rats. J. Neurosci. 1991, 11:852-868.
33. Cohen S.P., Bogduk N., Dragovich A., Buckenmaier C.C., Griffith S., Kurihara C., Raymond J., Richter P.J., Williams N., Yaksh T.L. Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Anesthesiology 2009, 110:1116-1126.
34. Colla M., Kronenberg G., Deuschle M., Meichel K., Hagen T., Bohrer M., Heuser I. Hippocampal volume reduction and HPA-system activity in major depression. J. Psychiatr. Res. 2007, 41:553-560.
35. Conrad C.D., LeDoux J.E., Magarinos A.M., McEwen B.S. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav. Neurosci. 1999, 113:902-913.
36. Correll G.E., Maleki J., Gracely E.J., Muir J.J., Harbut R.E. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel therapeutic approach to complex regional pain syndrome. Pain Med. 2004, 5:263-275.
37. Covey W.C., Ignatowski T.A., Knight P.R., Spengler R.N. Brain-derived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res. 2000, 859:113-122.
38. Curet O., de Montigny C. Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus. II. Receptors mediating the effect of synaptically released norepinephrine. Brain Res. 1988, 475:47-57.
39. Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., Bartolomucci A., Fuchs E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12796-12801.
40. Dantzer R., Wollman E.E., Vitkovic L., Yirmiya R. Cytokines, stress, and depression. Conclusions and perspectives. Adv. Exp. Med. Biol. 1999, 461:317-329.
41. De Felipe C., Pinnock R.D., Hunt S.P. Modulation of chemotropism in the developing spinal cord by substance P. Science 1995, 267:899-902.
42. de Kloet E.R., Derijk R.H., Meijer O.C. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nature clinical practice. Endocrinol. Metab. 2007, 3:168-179.
43. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 2005, 6:463-475.
44. del Rey A., Yau H.J., Randolf A., Centeno M.V., Wildmann J., Martina M., Besedovsky H.O., Apkarian A.V. Chronic neuropathic pain-like behavior correlates with IL-1beta expression and disrupts cytokine interactions in the hippocampus. Pain 2011, 152:2827-2835.
45. Delbende C., Contesse V., Mocaer E., Kamoun A., Vaudry H. The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. Eur. J. Pharmacol. 1991, 202:391-396.
46. DeLeo J.A., Colburn R.W., Rickman A.J. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 1997, 759:50-57.
47. Dellarole A., Morton P., Brambilla R., Walters W., Summers S., Bernardes D., Grilli M., Bethea J.R. Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFR1 signaling. Brain Behav. Immun. 2014, 41:65-81.
48. Dixon W.R., Mosimann W.F., Weiner N. The role of presynatpic feedback mechanisms in regulation of norepinephrine release by nerve stimulation. J. Pharmacol. Exp. Ther. 1979, 209:196-204.
49. Duman R.S., Charney D.S. Cell atrophy and loss in major depression. Biol. Psychiatry 1999, 45:1083-1084.
50. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
51. Duric V., McCarson K.E. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience 2005, 133:999-1006.
52. Duric V., McCarson K.E. Effects of analgesic or antidepressant drugs on pain- or stress-evoked hippocampal and spinal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression in the rat. J. Pharmacol. Exp. Ther. 2006, 319:1235-1243.
53. Duric V., McCarson K.E. Persistent pain produces stress-like alterations in hippocampal neurogenesis and gene expression. J. Pain 2006, 7:544-555.
54. Duric V., McCarson K.E. Neurokinin-1 (NK-1) receptor and brain-derived neurotrophic factor (BDNF) gene expression is differentially modulated in the rat spinal dorsal horn and hippocampus during inflammatory pain. Mol. Pain 2007, 3:32-40.
55. Dworkin R.H., Gitlin M.J. Clinical aspects of depression in chronic pain patients. Clin J. Pain 1991, 7:79-94.
56. Eason M.G., Jacinto M.T., Liggett S.B. Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs. Mol. Pharmacol. 1994, 45:696-702.
57. Eason M.G., Kurose H., Holt B.D., Raymond J.R., Liggett S.B. Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J. Biol. Chem. 1992, 267:15795-15801.
58. Elenkov I.J., Kovacs K., Duda E., Stark E., Vizi E.S. Presynaptic inhibitory effect of TNF-alpha on the release of noradrenaline in isolated median eminence. J. Neuroimmunol. 1992, 41:117-120.
59. Elenkov I.J., Kovács K., Duda E., Stark E., Vizi E.S. Modulatory effect of TNF-α on the release of noradrenaline in isolated median eminence. Pharmacol. Res. 1992, 25(Suppl. 2):23-24.
60. Erickson K.I., Voss M.W., Prakash R.S., Basak C., Szabo A., Chaddock L., Kim J.S., Heo S., Alves H., White S.M., Wojcicki T.R., Mailey E., Vieira V.J., Martin S.A., Pence B.D., Woods J.A., McAuley E., Kramer A.F. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3017-3022.
61. Eriksson P.S., Perfilieva E., Bjork-Eriksson T., Alborn A.M., Nordborg C., Peterson D.A., Gage F.H. Neurogenesis in the adult human hippocampus. Nat. Med. 1998, 4:1313-1317.
62. Felger J.C., Lotrich F.E. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246:199-229.
63. Feng Y., LeBlanc M.H., Regunathan S. Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci. Lett. 2005, 390:129-133.
64. Feuerstein T.J., Gleichauf O., Landwehrmeyer G.B. Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons. Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 354:618-626.
65. Foltz E.L., White L.E. Pain "relief" by frontal cingulumotomy. J. Neurosurg. 1962, 19:89-100.
66. Frank M.G., Baratta M.V., Sprunger D.B., Watkins L.R., Maier S.F. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 2007, 21:47-59.
67. Frodl T.S., Koutsouleris N., Bottlender R., Born C., Jager M., Scupin I., Reiser M., Moller H.J., Meisenzahl E.M. Depression-related variation in brain morphology over 3 years: effects of stress?. Arch. Gen. Psychiatry 2008, 65:1156-1165.
68. Fukuhara K., Ishikawa K., Yasuda S., Kishishita Y., Kim H.K., Kakeda T., Yamamoto M., Norii T., Ishikawa T. Intracerebroventricular 4-methylcatechol (4-MC) ameliorates chronic pain associated with depression-like behavior via induction of brain-derived neurotrophic factor (BDNF). Cell. Mol. Neurobiol. 2012, 32:971-977.
69. Fundytus M.E., Yashpal K., Chabot J.G., Osborne M.G., Lefebvre C.D., Dray A., Henry J.L., Coderre T.J. Knockdown of spinal metabotropic glutamate receptor 1 (mGluR(1)) alleviates pain and restores opioid efficacy after nerve injury in rats. Br. J. Pharmacol. 2001, 132:354-367.
70. Furmaga H., Carreno F.R., Frazer A. Vagal nerve stimulation rapidly activates brain-derived neurotrophic factor receptor TrkB in rat brain. PLoS ONE 2012, 7:e34844.
71. Furukawa Y., Tomioka N., Sato W., Satoyoshi E., Hayashi K., Furukawa S. Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells. FEBS Lett. 1989, 247:463-467.
72. Gage F.H., Springer J.E. Behavioral assessment of norepinephrine and serotonin function and interaction in the hippocampal formation. Pharmacol. Biochem. Behav. 1981, 14:815-821.
73. Galli U., Gaab J., Ettlin D.A., Ruggia F., Ehlert U., Palla S. Enhanced negative feedback sensitivity of the hypothalamus-pituitary-adrenal axis in chronic myogenous facial pain. Eur. J. Pain 2009, 13:600-605.
74. Garcia L.S., Comim C.M., Valvassori S.S., Reus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G.R., Gavioli E.C., Kapczinski F., Quevedo J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuro-psychopharmacol. Biol. Psychiatry 2008, 32:140-144.
75. Gebhardt N., Bar K.J., Boettger M.K., Grecksch G., Keilhoff G., Reichart R., Becker A. Vagus nerve stimulation ameliorated deficits in one-way active avoidance learning and stimulated hippocampal neurogenesis in bulbectomized rats. Brain Stimul. 2013, 6:78-83.
76. George M.S., Rush A.J., Marangell L.B., Sackeim H.A., Brannan S.K., Davis S.M., Howland R., Kling M.A., Moreno F., Rittberg B., Dunner D., Schwartz T., Carpenter L., Burke M., Ninan P., Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol. Psychiatry 2005, 58:364-373.
77. Gilad G.M., Gilad V.H., Finberg J.P., Rabey J.M. Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem. Res. 2005, 30:713-719.
78. Gore M., Sadosky A., Stacey B.R., Tai K.S., Leslie D. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine 2012, 37:E668-E677.
79. Gould E. Serotonin and hippocampal neurogenesis. Neuropsychopharmacology 1999, 21:46S-51S.
80. Gould E., Beylin A., Tanapat P., Reeves A., Shors T.J. Learning enhances adult neurogenesis in the hippocampal formation. Nat. Neurosci. 1999, 2:260-265.
81. Greene S.A. Chronic pain: pathophysiology and treatment implications. Top. Companion Anim. Med. 2010, 25:5-9.
82. Halaris A., Piletz J.E. Relevance of imidazoline receptors and agmatine to psychiatry: a decade of progress. Ann. N.Y. Acad. Sci. 2003, 1009:1-20.
83. Halaris A., Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 2007, 21:885-900.
84. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
85. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur. Neuropsychopharmacol. 2004, 14:274-281.
86. Harro J., Oreland L. Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. Brain Res. Rev. 2001, 38:79-128.
87. Hasler G., Fromm S., Alvarez R.P., Luckenbaugh D.A., Drevets W.C., Grillon C. Cerebral blood flow in immediate and sustained anxiety. J. Neurosci. 2007, 27:6313-6319.
88. Heiberg I.L., Wegener G., Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav. Brain Res. 2002, 134:479-484.
89. Henn F.A., Vollmayr B. Stress models of depression: forming genetically vulnerable strains. Neurosci. Biobehav. Rev. 2005, 29:799-804.
90. Herpfer I., Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 2005, 19:275-293.
91. Hess A., Axmann R., Rech J., Finzel S., Heindl C., Kreitz S., Sergeeva M., Saake M., Garcia M., Kollias G., Straub R.H., Sporns O., Doerfler A., Brune K., Schett G. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3731-3736.
92. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 2003, 19:183-188.
93. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., Kloiber S., Lucae S., Ising M., Uhr M., Holsboer F., Pollmacher T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 2008, 23:421-429.
94. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
95. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 1996, 17:187-205.
96. Hord E.D., Evans M.S., Mueed S., Adamolekun B., Naritoku D.K. The effect of vagus nerve stimulation on migraines. J. Pain 2003, 4:530-534.
97. Hyland N.P., O'Mahony S.M., O'Malley D., O'Mahony C.M., Dinan T.G., Cryan J.F. Early-life stress selectively affects gastrointestinal but not behavioral responses in a genetic model of brain-gut axis dysfunction. Neurogastroenterol. Motil. 2015, 27:105-113.
98. Iannone F., Trotta F., Montecucco C., Giacomelli R., Galeazzi M., Matucci-Cerinic M., Ferri C., Cutolo M., Maria Bambara L., Triolo G., Ferraccioli G., Valentini G., Lapadula G. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann. Rheum. Dis. 2007, 66:249-252.
99. Ignatowski T.A., Chou R.C., Spengler R.N. Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine. J. Neuroimmunol. 1996, 70:55-63.
100. Ignatowski T.A., Covey W.C., Knight P.R., Severin C.M., Nickola T.J., Spengler R.N. Brain-derived TNFalpha mediates neuropathic pain. Brain Res. 1999, 841:70-77.
101. Ignatowski T.A., Noble B.K., Wright J.R., Gorfien J.L., Heffner R.R., Spengler R.N. Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J. Neuroimmunol. 1997, 79:84-90.
102. Ignatowski T.A., Noble B.K., Wright J.R., Gorfien J.L., Spengler R.N. TNFalpha: a neuromodulator in the central nervous system. Adv. Exp. Med. Biol. 1996, 402:219-224.
103. Ignatowski T.A., Spengler R.N. Tumor necrosis factor-alpha: presynaptic sensitivity is modified after antidepressant drug administration. Brain Res. 1994, 665:293-299.
104. Ignatowski T.A., Sud R., Reynolds J.L., Knight P.R., Spengler R.N. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). Neuropharmacology 2005, 48:448-460.
105. Institute of Medicine (IOM) Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research 2011, The National Academies Press, Washington, DC.
106. Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J., Bonde S., Kokaia Z., Jacobsen S.E., Lindvall O. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci. 2006, 26:9703-9712.
107. Ito M., Seki T., Liu J., Nakamura K., Namba T., Matsubara Y., Suzuki T., Arai H. Effects of repeated electroconvulsive seizure on cell proliferation in the rat hippocampus. Synapse 2010, 64:814-821.
108. Iyo A.H., Zhu M.Y., Ordway G.A., Regunathan S. Expression of arginine decarboxylase in brain regions and neuronal cells. J. Neurochem. 2006, 96:1042-1050.
109. Janig W., Baron R. Complex regional pain syndrome: mystery explained?. Lancet Neurol. 2003, 2:687-697.
110. Jensen M.P., Chodroff M.J., Dworkin R.H. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007, 68:1178-1182.
111. Jensen T.S., Baron R., Haanpaa M., Kalso E., Loeser J.D., Rice A.S., Treede R.D. A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
112. Jessop D.S., Renshaw D., Larsen P.J., Chowdrey H.S., Harbuz M.S. Substance P is involved in terminating the hypothalamo-pituitary-adrenal axis response to acute stress through centrally located neurokinin-1 receptors. Stress 2000, 3:209-220.
113. Jones S.L., Gebhart G.F. Quantitative characterization of ceruleospinal inhibition of nociceptive transmission in the rat. J. Neurophysiol. 1986, 56:1397-1410.
114. Jorum E., Warncke T., Stubhaug A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-d-aspartate (NMDA) receptor antagonist ketamine - a double-blind, cross-over comparison with alfentanil and placebo. Pain 2003, 101:229-235.
115. Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res. Mol. Brain Res. 2005, 136:29-37.
116. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
117. Kee N., Sivalingam S., Boonstra R., Wojtowicz J.M. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J. Neurosci. Methods 2002, 115:97-105.
118. Kempermann G., Kronenberg G. Depressed new neurons - adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol. Psychiatry 2003, 54:499-503.
119. Kennedy P.J., Clarke G., Quigley E.M., Groeger J.A., Dinan T.G., Cryan J.F. Gut memories: towards a cognitive neurobiology of irritable bowel syndrome. Neurosci. Biobehav. Rev. 2012, 36:310-340.
120. Khanna S., Sinclair J.G. Noxious stimuli produce prolonged changes in the CA1 region of the rat hippocampus. Pain 1989, 39:337-343.
121. Khoa N.D., Postow M., Danielsson J., Cronstein B.N. Tumor necrosis factor-alpha prevents desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma membrane. Mol. Pharmacol. 2006, 69:1311-1319.
122. Kim H., Chen L., Lim G., Sung B., Wang S., McCabe M.F., Rusanescu G., Yang L., Tian Y., Mao J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Investig. 2012, 122:2940-2954.
123. Klein J.B., Scherzer J.A., Harding G., Jacobs A.A., McLeish K.R. TNF-alpha stimulates increased plasma membrane guanine nucleotide binding protein activity in polymorphonuclear leukocytes. J. Leukoc. Biol. 1995, 57:500-506.
124. Kodama D., Ono H., Tanabe M. Altered hippocampal long-term potentiation after peripheral nerve injury in mice. Eur. J. Pharmacol. 2007, 574:127-132.
125. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 2011, 224:107-111.
126. Korhonen T., Karppinen J., Paimela L., Malmivaara A., Lindgren K.A., Bowman C., Hammond A., Kirkham B., Jarvinen S., Niinimaki J., Veeger N., Haapea M., Torkki M., Tervonen O., Seitsalo S., Hurri H. The treatment of disc-herniation-induced sciatica with infliximab: one-year follow-up results of FIRST II, a randomized controlled trial. Spine 2006, 31:2759-2766.
127. Korhonen T., Karppinen J., Paimela L., Malmivaara A., Lindgren K.A., Jarvinen S., Niinimaki J., Veeger N., Seitsalo S., Hurri H. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine 2005, 30:2724-2728.
128. Kourounakis A., Bodor N., Simpkins J. Synthesis and evaluation of brain-targeted chemical delivery systems for the neurotrophomodulator 4-methylcatechol. J. Pharm. Pharmacol. 1997, 49:1-9.
129. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCoss M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281:1640-1645.
130. Kraychete D.C., Sakata R.K., Issy A.M., Bacellar O., Santos-Jesus R., Carvalho E.M. Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study. Sao Paulo Med. J. 2010, 128:259-262.
131. Krugel U., Fischer J., Radicke S., Sack U., Himmerich H. Antidepressant effects of TNF-alpha blockade in an animal model of depression. J. Psychiatr. Res. 2013, 47:611-616.
132. Kuwatsuka K., Hayashi H., Onoue Y., Miyazaki I., Koyama T., Asanuma M., Kitamura Y., Sendo T. The mechanisms of electroconvulsive stimuli in BrdU-positive cells of the dentate gyrus in ACTH-treated rats. J. Pharmacol. Sci. 2013, 122:34-41.
133. LaBuda C.J., Koblish M., Tuthill P., Dolle R.E., Little P.J. Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and post-operative pain. Eur. J. Pain 2006, 10:505-512.
134. Lathe R. Hormones and the hippocampus. J. Endocrinol. 2001, 169:205-231.
135. Lawlor P.G. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer 2002, 94:1836-1853.
136. Li B., Suemaru K., Cui R., Araki H. Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci. 2007, 80:1539-1543.
137. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., Li X.Y., Aghajanian G., Duman R.S. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
138. Li Y.F., Gong Z.H., Cao J.B., Wang H.L., Luo Z.P., Li J. Antidepressant-like effect of agmatine and its possible mechanism. Eur. J. Pharmacol. 2003, 469:81-88.
139. Lichtenstein G.R., Bala M., Han C., DeWoody K., Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm. Bowel Dis. 2002, 8:237-243.
140. Lieb K., Ahlvers K., Dancker K., Strohbusch S., Reincke M., Feige B., Berger M., Riemann D., Voderholzer U. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology 2002, 27:1041-1049.
141. Lonze B.E., Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002, 35:605-623.
142. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 1998, 43:547-573.
143. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. 2001, 26:30-36.
144. Lyons D.M., Yang C., Sawyer-Glover A.M., Moseley M.E., Schatzberg A.F. Early life stress and inherited variation in monkey hippocampal volumes. Arch. Gen. Psychiatry 2001, 58:1145-1151.
145. MacQueen G.M., Campbell S., McEwen B.S., Macdonald K., Amano S., Joffe R.T., Nahmias C., Young L.T. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1387-1392.
146. Madrigal J.L., Hurtado O., Moro M.A., Lizasoain I., Lorenzo P., Castrillo A., Bosca L., Leza J.C. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 2002, 26:155-163.
147. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., Manji H.K. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 2008, 63:349-352.
148. Maes M., Kenis G., Kubera M., De Baets M., Steinbusch H., Bosmans E. The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway. Int. Immunopharmacol. 2005, 5:609-618.
149. Magarinos A.M., Deslandes A., McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur. J. Pharmacol. 1999, 371:113-122.
150. Magarinos A.M., Verdugo J.M., McEwen B.S. Chronic stress alters synaptic terminal structure in hippocampus. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14002-14008.
151. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol. Rev. 1998, 105:83-107.
152. Maletic V., Robinson M., Oakes T., Iyengar S., Ball S.G., Russell J. Neurobiology of depression: an integrated view of key findings. Int. J. Clin. Pract. 2007, 61:2030-2040.
153. Manta S., El Mansari M., Debonnel G., Blier P. Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. Int. J. Neuropsychopharmacol. 2013, 16:459-470.
154. Martelli M.F., Zasler N.D., Bender M.C., Nicholson K. Psychological, neuropsychological, and medical considerations in assessment and management of pain. J. Head Trauma Rehabil. 2004, 19:10-28.
155. Martenson M.E., Cetas J.S., Heinricher M.M. A possible neural basis for stress-induced hyperalgesia. Pain 2009, 142:236-244.
156. Martinez J.M., Garakani A., Yehuda R., Gorman J.M. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress. Anxiety 2012, 29:32-38.
157. Martinowich K., Manji H., Lu B. New insights into BDNF function in depression and anxiety. Nat. Neurosci. 2007, 10:1089-1093.
158. Martuscello R.T., Spengler R.N., Bonoiu A.C., Davidson B.A., Helinski J., Ding H., Mahajan S., Kumar R., Bergey E.J., Knight P.R., Prasad P.N., Ignatowski T.A. Increasing TNF levels solely in the rat hippocampus produces persistent pain-like symptoms. Pain 2012, 153:1871-1882.
159. Mathias S.D., Colwell H.H., Miller D.P., Moreland L.W., Buatti M., Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin. Ther. 2000, 22:128-139.
160. McEwen B.S. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 1999, 22:105-122.
161. McEwen B.S. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann. N.Y. Acad. Sci. 2001, 933:265-277.
162. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54:20-23.
163. McEwen B.S., Biron C.A., Brunson K.W., Bulloch K., Chambers W.H., Dhabhar F.S., Goldfarb R.H., Kitson R.P., Miller A.H., Spencer R.L., Weiss J.M. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res. Brain Res. Rev. 1997, 23:79-133.
164. McEwen B.S., Kalia M. The role of corticosteroids and stress in chronic pain conditions. Metabolism 2010, 59(Suppl. 1):S9-S15.
165. McEwen B.S., Seeman T. Protective and damaging effects of mediators of stress. Elaborating and testing the concepts of allostasis and allostatic load. Ann. N.Y. Acad. Sci. 1999, 896:30-47.
166. McKenna J.E., Melzack R. Analgesia produced by lidocaine microinjection into the dentate gyrus. Pain 1992, 49:105-112.
167. McKenna J.E., Melzack R. Blocking NMDA receptors in the hippocampal dentate gyrus with AP5 produces analgesia in the formalin pain test. Exp. Neurol. 2001, 172:92-99.
168. McKittrick C.R., Magarinos A.M., Blanchard D.C., Blanchard R.J., McEwen B.S., Sakai R.R. Chronic social stress reduces dendritic arbors in CA3 of hippocampus and decreases binding to serotonin transporter sites. Synapse 2000, 36:85-94.
169. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain 1996, 68:217-227.
170. Metz A.E., Yau H.J., Centeno M.V., Apkarian A.V., Martina M. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2423-2428.
171. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., Young T., Praschak-Rieder N., Wilson A.A., Houle S. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch. Gen. Psychiatry 2006, 63:1209-1216.
172. Meyers C.A. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv. Exp. Med. Biol. 1999, 461:75-81.
173. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001, 11:203-208.
174. Millan M.J. Descending control of pain. Prog. Neurobiol. 2002, 66:355-474.
175. Mirescu C., Gould E. Stress and adult neurogenesis. Hippocampus 2006, 16:233-238.
176. Mizuno M., Yamada K., Maekawa N., Saito K., Seishima M., Nabeshima T. CREB phosphorylation as a molecular marker of memory processing in the hippocampus for spatial learning. Behav. Brain Res. 2002, 133:135-141.
177. Moghaddam B., Bolinao M.L., Stein-Behrens B., Sapolsky R. Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate. Brain Res. 1994, 655:251-254.
178. Moloney R.D., O'Leary O.F., Felice D., Bettler B., Dinan T.G., Cryan J.F. Early-life stress induces visceral hypersensitivity in mice. Neurosci. Lett. 2012, 512:99-102.
179. Moriarty O., McGuire B.E., Finn D.P. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog. Neurobiol. 2011, 93:385-404.
180. Mulleman D., Mammou S., Griffoul I., Watier H., Goupille P. Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. Joint Bone Spine: Rev. Rhum. 2006, 73:270-277.
181. Multon S., Schoenen J. Pain control by vagus nerve stimulation: from animal to man. . .and back. Acta Neurol. Belg. 2005, 105:62-67.
182. Murray C.J.L., Lopez A.D., Harvard School of Public Health, World Health Organization, World Bank The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020 [Cambridge, MA] 1996, Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank; Distributed by Harvard University Press, c1996.
183. Mutso A.A., Petre B., Huang L., Baliki M.N., Torbey S., Herrmann K.M., Schnitzer T.J., Apkarian A.V. Reorganization of hippocampal functional connectivity with transition to chronic back pain. J. Neurophysiol. 2014, 111:1065-1076.
184. Mutso A.A., Radzicki D., Baliki M.N., Huang L., Banisadr G., Centeno M.V., Radulovic J., Martina M., Miller R.J., Apkarian A.V. Abnormalities in hippocampal functioning with persistent pain. J. Neurosci. 2012, 32:5747-5756.
185. Nadeau S., Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci. 2003, 23:5536-5544.
186. Nader N.D., Ignatowski T.A., Kurek C.J., Knight P.R., Spengler R.N. Clonidine suppresses plasma and cerebrospinal fluid concentrations of TNF-alpha during the perioperative period. Anesth. Analg. 2001, 93:363-369.
187. Nagakura Y., Oe T., Aoki T., Matsuoka N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia. Pain 2009, 146:26-33.
188. Nakagawa S., Kim J.E., Lee R., Malberg J.E., Chen J., Steffen C., Zhang Y.J., Nestler E.J., Duman R.S. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 2002, 22:3673-3682.
189. Napadow V., Edwards R.R., Cahalan C.M., Mensing G., Greenbaum S., Valovska A., Li A., Kim J., Maeda Y., Park K., Wasan A.D. Evoked pain analgesia in chronic pelvic pain patients using respiratory-gated auricular vagal afferent nerve stimulation. Pain Med. 2012, 13:777-789.
190. Neumeister A., Wood S., Bonne O., Nugent A.C., Luckenbaugh D.A., Young T., Bain E.E., Charney D.S., Drevets W.C. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol. Psychiatry 2005, 57:935-937.
191. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
192. Nickola T.J., Ignatowski T.A., Reynolds J.L., Spengler R.N. Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. J. Pharmacol. Exp. Ther. 2001, 297:680-687.
193. Nickola T.J., Ignatowski T.A., Spengler R.N. Antidepressant drug administration modifies the interactive relationship between alpha(2)-adrenergic sensitivity and levels of TNF in the rat brain. J. Neuroimmunol. 2000, 107:50-58.
194. Niddam D.M., Tsai S.Y., Lu C.L., Ko C.W., Hsieh J.C. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome: preliminary findings using magnetic resonance spectroscopy. Am. J. Gastroenterol. 2011, 106:1503-1511.
195. NIH MedlinePlus [The Magazine] Chronic pain: symptoms, diagnosis, & treatment. National Institutes of Health and National Library of Medicine. NIH MedlinePlus Spring 2011, 6(1):5-6.
196. Nussdorfer G.G., Malendowicz L.K. Role of tachykinins in the regulation of the hypothalamo-pituitary-adrenal axis. Peptides 1998, 19:949-968.
197. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 2007, 41:326-331.
198. O'Connor K.A., Johnson J.D., Hansen M.K., Wieseler Frank J.L., Maksimova E., Watkins L.R., Maier S.F. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res. 2003, 991:123-132.
199. O'Leary O.F., Cryan J.F. A ventral view on antidepressant action: roles for adult hippocampal neurogenesis along the dorsoventral axis. Trends Pharmacol. Sci. 2014, 35:675-687.
200. O'Mahony S.M., Coelho A.M., Fitzgerald P., Lee K., Winchester W., Dinan T.G., Cryan J.F. The effects of gabapentin in two animal models of co-morbid anxiety and visceral hypersensitivity. Eur. J. Pharmacol. 2011, 667:169-174.
201. O'Mahony S.M., Marchesi J.R., Scully P., Codling C., Ceolho A.M., Quigley E.M., Cryan J.F., Dinan T.G. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol. Psychiatry 2009, 65:263-267.
202. Oka T., Wakugawa Y., Hosoi M., Oka K., Hori T. Intracerebroventricular injection of tumor necrosis factor-alpha induces thermal hyperalgesia in rats. Neuroimmunomodulation 1996, 3:135-140.
203. Onda A., Murata Y., Rydevik B., Larsson K., Kikuchi S., Olmarker K. Infliximab attenuates immunoreactivity of brain-derived neurotrophic factor in a rat model of herniated nucleus pulposus. Spine 2004, 29:1857-1861.
204. Pacak K., Palkovits M., Kopin I.J., Goldstein D.S. Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. Front. Neuroendocrinol. 1995, 16:89-150.
205. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
206. Pancner R.J., Jylland C.W. Depressive disorders. Psychopathology and Psychotherapy - From DSM-IV Diagnosis to Treatment 1996, 115-157. L. Sperry, J. Carlson (Eds.).
207. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 2001, 49:391-404.
208. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol. Pharmacol. 1997, 52:571-581.
209. Pauwels P.J., Tardif S., Colpaert F.C., Wurch T. Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins. Biochem. Pharmacol. 2001, 61:1079-1092.
210. Pencea V., Bingaman K.D., Wiegand S.J., Luskin M.B. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J. Neurosci. 2001, 21:6706-6717.
211. Piletz J.E., May P.J., Wang G., Zhu H. Agmatine crosses the blood-brain barrier. Ann. N.Y. Acad. Sci. 2003, 1009:64-74.
212. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
213. Raison C.L., Miller A.H. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 2003, 160:1554-1565.
214. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
215. Raiteri M., Maura G., Folghera S., Cavazzani P., Andrioli G.C., Schlicker E., Schalnus R., Gothert M. Modulation of 5-hydroxytryptamine release by presynaptic inhibitory alpha 2-adrenoceptors in the human cerebral cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990, 342:508-512.
216. Regunathan S., Piletz J.E. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann. N.Y. Acad. Sci. 2003, 1009:20-29.
217. Reithmann C., Gierschik P., Jakobs K.H., Werdan K. Regulation of adenylyl cyclase by noradrenaline and tumour necrosis factor alpha in rat cardiomyocytes. Eur. Heart J. 1991, 12(Suppl. F):139-142.
218. Ren K., Dubner R. Descending modulation in persistent pain: an update. Pain 2002, 100:1-6.
219. Ren W.H., Guo J.D., Cao H., Wang H., Wang P.F., Sha H., Ji R.R., Zhao Z.Q., Zhang Y.Q. Is endogenous d-serine in the rostral anterior cingulate cortex necessary for pain-related negative affect?. J. Neurochem. 2006, 96:1636-1647.
220. Ren W.J., Liu Y., Zhou L.J., Li W., Zhong Y., Pang R.P., Xin W.J., Wei X.H., Wang J., Zhu H.Q., Wu C.Y., Qin Z.H., Liu G., Liu X.G. Peripheral nerve injury leads to working memory deficits and dysfunction of the hippocampus by upregulation of TNF-alpha in rodents. Neuropsychopharmacology 2011, 36:979-992.
221. Renauld A.E., Ignatowski T.A., Spengler R.N. Alpha 2-adrenergic receptor inhibition of cAMP accumulation is transformed to facilitation by tumor necrosis factor-alpha. Brain Res. 2004, 1004:212-216.
222. Renauld A.E., Spengler R.N. Tumor necrosis factor expressed by primary hippocampal neurons and SH-SY5Y cells is regulated by alpha(2)-adrenergic receptor activation. J. Neurosci. Res. 2002, 67:264-274.
223. Reynolds J.L., Ignatowski T.A., Gallant S., Spengler R.N. Amitriptyline administration transforms tumor necrosis factor-alpha regulation of norepinephrine release in the brain. Brain Res. 2004, 1023:112-120.
224. Reynolds J.L., Ignatowski T.A., Spengler R.N. Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor. J. Neurosci. Res. 2005, 79:779-787.
225. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J. Pharmacol. Exp. Ther. 2004, 310:1216-1225.
226. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005, 133:519-531.
227. Robinson M.J., Edwards S.E., Iyengar S., Bymaster F., Clark M., Katon W. Depression and pain. Front. Biosci. 2009, 14:5031-5051.
228. Rupniak N.M. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Investig. Drugs 2002, 3:257-261.
229. Rupniak N.M., Kramer M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 1999, 20:485-490.
230. Rush A.J., Marangell L.B., Sackeim H.A., George M.S., Brannan S.K., Davis S.M., Howland R., Kling M.A., Rittberg B.R., Burke W.J., Rapaport M.H., Zajecka J., Nierenberg A.A., Husain M.M., Ginsberg D., Cooke R.G. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry 2005, 58:347-354.
231. Russell I.J. The promise of substance P inhibitors in fibromyalgia. Rheum. Dis. Clin. North Am. 2002, 28:329-342.
232. Russo-Neustadt A., Ha T., Ramirez R., Kesslak J.P. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav. Brain Res. 2001, 120:87-95.
233. Sairanen M., Lucas G., Ernfors P., Castren M., Castren E. Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus. J. Neurosci. 2005, 25:1089-1094.
234. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
235. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
236. Sapolsky R.M. Stress, glucocorticoids, and damage to the nervous system: the current state of confusion. Stress 1996, 1:1-19.
237. Sapolsky R.M., Uno H., Rebert C.S., Finch C.E. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J. Neurosci. 1990, 10:2897-2902.
238. Sasaki H., Kihara M., Zollman P.J., Nickander K.K., Smithson I.L., Schmelzer J.D., Willner C.L., Benarroch E.E., Low P.A. Chronic constriction model of rat sciatic nerve: nerve blood flow, morphologic and biochemical alterations. Acta Neuropathol. 1997, 93:62-70.
239. Sasaki N., Kikuchi S., Konno S., Sekiguchi M., Watanabe K. Anti-TNF-alpha antibody reduces pain-behavioral changes induced by epidural application of nucleus pulposus in a rat model depending on the timing of administration. Spine 2007, 32:413-416.
240. Satriano J., Schwartz D., Ishizuka S., Lortie M.J., Thomson S.C., Gabbai F., Kelly C.J., Blantz R.C. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. J. Cell. Physiol. 2001, 188:313-320.
241. Sawynok J., Reid A. Modulation of formalin-induced behaviors and edema by local and systemic administration of dextromethorphan, memantine and ketamine. Eur. J. Pharmacol. 2002, 450:153-162.
242. Scharfman H., Goodman J., Macleod A., Phani S., Antonelli C., Croll S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp. Neurol. 2005, 192:348-356.
243. Scherzer J.A., Lin Y., McLeish K.R., Klein J.B. TNF translationally modulates the expression of G1 protein alpha(i2) subunits in human polymorphonuclear leukocytes. J. Immunol. 1997, 158:913-918.
244. Schrocksnadel K., Wirleitner B., Winkler C., Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 2006, 364:82-90.
245. Schulte-Herbruggen O., Nassenstein C., Lommatzsch M., Quarcoo D., Renz H., Braun A. Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 2005, 160:204-209.
246. Severn A., Rapson N.T., Hunter C.A., Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J. Immunol. 1992, 148:3441-3445.
247. Sheline Y.I., Gado M.H., Kraemer H.C. Untreated depression and hippocampal volume loss. Am. J. Psychiatry 2003, 160:1516-1518.
248. Sheline Y.I., Wang P.W., Gado M.H., Csernansky J.G., Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3908-3913.
249. Sherington C. The Integrative Action of the Nervous System 1906, Charles Scribner's Sons, New York.
250. Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., Nakazato M., Watanabe H., Shinoda N., Okada S., Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiatry 2003, 54:70-75.
251. Shirayama Y., Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
252. Siever L.J., Davis K.L. Overview: toward a dysregulation hypothesis of depression. Am. J. Psychiatry 1985, 142:1017-1031.
253. Soleimannejad E., Semnanian S., Fathollahi Y., Naghdi N. Microinjection of ritanserin into the dorsal hippocampal CA1 and dentate gyrus decrease nociceptive behavior in adult male rat. Behav. Brain Res. 2006, 168:221-225.
254. Sommer C., Lindenlaub T., Teuteberg P., Schafers M., Hartung T., Toyka K.V. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001, 913:86-89.
255. Sommer C., Marziniak M., Myers R.R. The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve. Pain 1998, 74:83-91.
256. Spengler R.N., Allen R.M., Remick D.G., Strieter R.M., Kunkel S.L. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol. 1990, 145:1430-1434.
257. Spengler R.N., Sud R., Knight P.R., Ignatowski T.A. Antinociception mediated by alpha(2)-adrenergic activation involves increasing tumor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine release. Neuropharmacology 2007, 52:576-589.
258. Spooren W., Ballard T., Gasparini F., Amalric M., Mutel V., Schreiber R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav. Pharmacol. 2003, 14:257-277.
259. Stanfa L., Dickenson A., Xu X.J., Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 1994, 15:65-66.
260. Stockmeier C.A., Mahajan G.J., Konick L.C., Overholser J.C., Jurjus G.J., Meltzer H.Y., Uylings H.B., Friedman L., Rajkowska G. Cellular changes in the postmortem hippocampus in major depression. Biol. Psychiatry 2004, 56:640-650.
261. Strange B.A., Witter M.P., Lein E.S., Moser E.I. Functional organization of the hippocampal longitudinal axis. Nat. Rev. Neurosci. 2014, 15:655-669.
262. Sud R., Ignatowski T.A., Lo C.P., Spengler R.N. Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain. Brain Behav. Immun. 2007, 21:112-124.
263. Sud R., Spengler R.N., Nader N.D., Ignatowski T.A. Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes/macrophages from pro- to anti-inflammatory. Eur. J. Pharmacol. 2008, 588:217-231.
264. Suzuki K., Ebina Y., Shindo T., Takano T., Awata S., Matsuoka H. Repeated electroconvulsive therapy courses improved chronic regional pain with depression caused by failed back syndrome. Med. Sci. Monit. 2009, 15:CS77-CS79.
265. Suzuki R., Morcuende S., Webber M., Hunt S.P., Dickenson A.H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat. Neurosci. 2002, 5:1319-1326.
266. Taliaz D., Nagaraj V., Haramati S., Chen A., Zangen A. Altered brain-derived neurotrophic factor expression in the ventral tegmental area, but not in the hippocampus, is essential for antidepressant-like effects of electroconvulsive therapy. Biol. Psychiatry 2013, 74:305-312.
267. Tanapat P., Galea L.A., Gould E. Stress inhibits the proliferation of granule cell precursors in the developing dentate gyrus. Int. J. Dev. Neurosci. 1998, 16:235-239.
268. Tanti A., Belzung C. Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific?. Neuroscience 2013, 252:234-252.
269. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., Storm D., Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 2000, 20:4030-4036.
270. Tizabi Y., Bhatti B.H., Manaye K.F., Das J.R., Akinfiresoye L. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 2012, 213:72-80.
271. Tobinick E., Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr. Med. Res. Opin. 2004, 20:1075-1085.
272. Tobinick E., Kim N.M., Reyzin G., Rodriguez-Romanacce H., DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 2012, 26:1051-1070.
273. Tobinick E.L. Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults. Clin. Ther. 2003, 25:1211-1218.
274. Ulrich-Lai Y.M., Xie W., Meij J.T., Dolgas C.M., Yu L., Herman J.P. Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiol. Behav. 2006, 88:67-76.
275. Unnerstall J.R., Kopajtic T.A., Kuhar M.J. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. 1984, 319:69-101.
276. Uzbay T.I. The pharmacological importance of agmatine in the brain. Neurosci. Biobehav. Rev. 2012, 36:502-519.
277. Van Kolen K., Pullan S., Neefs J.M., Dautzenberg F.M. Nociceptive and behavioural sensitisation by protein kinase C epsilon signalling in the CNS. J. Neurochem. 2008, 104:1-13.
278. Vanderah T.W. Pathophysiology of pain. Med. Clin. North Am. 2007, 91:1-12.
279. Walker A.K., Kavelaars A., Heijnen C.J., Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol. Rev. 2014, 66:80-101.
280. Wang J., Goffer Y., Xu D., Tukey D.S., Shamir D.B., Eberle S.E., Zou A.H., Blanck T.J., Ziff E.B. A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 2011, 115:812-821.
281. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
282. Wasan A.D., Artin K., Clark M.R. A case-matching study of the analgesic properties of electroconvulsive therapy. Pain Med. 2004, 5:50-58.
283. Watanabe Y., Gould E., McEwen B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992, 588:341-345.
284. Weiland N.G., Orchinik M., Tanapat P. Chronic corticosterone treatment induces parallel changes in N-methyl-d-aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus. Neuroscience 1997, 78:653-662.
285. Whiteside G.T., Dwyer J.M., Harrison J.E., Beyer C.E., Cummons T., Manzino L., Mark L., Johnston G.H., Strassle B.W., Adedoyin A., Lu P., Piesla M.J., Pulicicchio C.M., Erve J.C., Platt B.J., Hughes Z.A., Rogers K.E., Deecher D.C., Trybulski E.J., Kennedy J.D., Zhang P., Leventhal L. WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression. Br. J. Pharmacol. 2010, 160:1105-1118.
286. Wichers M., Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 2002, 5:375-388.
287. Wilson K.G., Mikail S.F., D'Eon J.L., Minns J.E. Alternative diagnostic criteria for major depressive disorder in patients with chronic pain. Pain 2001, 91:227-234.
288. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev. Neurother. 2008, 8:781-797.
289. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765-1769.
290. Wu N., Su R.B., Xu B., Lu X.Q., Liu Y., Zheng J.Q., Piletz J.E., Li J., Qin B.Y. IRAS, a candidate for I1-imidazoline receptor, mediates inhibitory effect of agmatine on cellular morphine dependence. Biochem. Pharmacol. 2005, 70:1079-1087.
291. Xiao W.H., Wagner R., Myers R.R., Sorkin L.S. TNF-α applied to the sciatic nerve trunk elicits background firing in nociceptive primary afferent fibers. Proceeding of the 8th World Congress on Pain 1996, 293-303. International Association for the Study of Pain (IASP).
292. Xu Y., Zhang L., Shao T., Ruan L., Wang L., Sun J., Li J., Zhu X., O'Donnell J.M., Pan J. Ferulic acid increases pain threshold and ameliorates depression-like behaviors in reserpine-treated mice: behavioral and neurobiological analyses. Metab. Brain Dis. 2013, 28:571-583.
293. Yalcin I., Barthas F., Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci. Biobehav. Rev. 2014, 47:154-164.
294. Yalcin I., Bohren Y., Waltisperger E., Sage-Ciocca D., Yin J.C., Freund-Mercier M.J., Barrot M. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biol. Psychiatry 2011, 70:946-953.
295. Yan Q., Rosenfeld R.D., Matheson C.R., Hawkins N., Lopez O.T., Bennett L., Welcher A.A. Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system. Neuroscience 1997, 78:431-448.
296. Yang C., Hu Y.M., Zhou Z.Q., Zhang G.F., Yang J.J. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Upsala J. Med. Sci. 2013, 118:3-8.
297. Yang X.C., Reis D.J. Agmatine selectively blocks the N-methyl-d-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 1999, 288:544-549.
298. Yilmaz P., Diers M., Diener S., Rance M., Wessa M., Flor H. Brain correlates of stress-induced analgesia. Pain 2010, 151:522-529.
299. Ying S.W., Futter M., Rosenblum K., Webber M.J., Hunt S.P., Bliss T.V., Bramham C.R. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J. Neurosci. 2002, 22:1532-1540.
300. Zhu M.Y., Wang W.P., Bissette G. Neuroprotective effects of agmatine against cell damage caused by glucocorticoids in cultured rat hippocampal neurons. Neuroscience 2006, 141:2019-2027.
301. Zimmerman M.E., Pan J.W., Hetherington H.P., Lipton M.L., Baigi K., Lipton R.B. Hippocampal correlates of pain in healthy elderly adults: a pilot study. Neurology 2009, 73:1567-1570.